NO180191C - Hydrazonderivater, farmasöytiske preparater derav samt anvendelse av hydrazonforbindelser for fremstilling av et medikament - Google Patents
Hydrazonderivater, farmasöytiske preparater derav samt anvendelse av hydrazonforbindelser for fremstilling av et medikamentInfo
- Publication number
- NO180191C NO180191C NO921000A NO921000A NO180191C NO 180191 C NO180191 C NO 180191C NO 921000 A NO921000 A NO 921000A NO 921000 A NO921000 A NO 921000A NO 180191 C NO180191 C NO 180191C
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- hydrogen
- independently
- compounds
- benzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Holo Graphy (AREA)
- Cephalosporin Compounds (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/670,061 US5164404A (en) | 1991-03-15 | 1991-03-15 | Hydrazone derivatives and their use |
Publications (4)
Publication Number | Publication Date |
---|---|
NO921000D0 NO921000D0 (no) | 1992-03-13 |
NO921000L NO921000L (no) | 1992-09-16 |
NO180191B NO180191B (no) | 1996-11-25 |
NO180191C true NO180191C (no) | 1997-03-05 |
Family
ID=24688827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO921000A NO180191C (no) | 1991-03-15 | 1992-03-13 | Hydrazonderivater, farmasöytiske preparater derav samt anvendelse av hydrazonforbindelser for fremstilling av et medikament |
Country Status (16)
Country | Link |
---|---|
US (1) | US5164404A (el) |
EP (1) | EP0503349B1 (el) |
JP (1) | JP3407896B2 (el) |
KR (1) | KR100192641B1 (el) |
AT (1) | ATE116639T1 (el) |
AU (1) | AU643877B2 (el) |
CA (1) | CA2062853A1 (el) |
DE (1) | DE69201068T2 (el) |
DK (1) | DK0503349T3 (el) |
ES (1) | ES2069330T3 (el) |
FI (1) | FI103276B1 (el) |
GR (1) | GR3015671T3 (el) |
IE (1) | IE66111B1 (el) |
NO (1) | NO180191C (el) |
NZ (1) | NZ241752A (el) |
ZA (1) | ZA921328B (el) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9109007D0 (en) * | 1991-04-26 | 1991-06-12 | Merck Sharp & Dohme | Therapeutic method |
AU655643B2 (en) * | 1991-07-09 | 1995-01-05 | Neurosearch A/S | Novel isatineoxime derivatives, their preparation and use |
DK69693D0 (da) * | 1993-06-14 | 1993-06-14 | Neurosearch As | Farven lilla |
US5565580A (en) * | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
US5773434A (en) * | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
KR19980050063A (ko) * | 1996-12-20 | 1998-09-15 | 이덕림 | 신규한 하이드라존 유도체 |
AR016384A1 (es) * | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
AR016551A1 (es) * | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
ATE249828T1 (de) | 1998-03-06 | 2003-10-15 | Astrazeneca Ab | Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen |
US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US6492398B1 (en) | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
EP1242081A4 (en) * | 1999-09-30 | 2004-07-21 | Smithkline Beecham Corp | CASPASES AND APOPTOSIS |
US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
US6589504B1 (en) * | 2000-09-22 | 2003-07-08 | Pharmacia & Upjohn Company | Compounds and methods for diagnosing and treating amyloid-related conditions |
WO2002070478A1 (en) | 2001-03-06 | 2002-09-12 | Astrazeneca Ab | Indolone derivatives having vascular-damaging activity |
BRPI0511057A (pt) * | 2004-05-12 | 2007-11-27 | Bayer Cropscience Gmbh | regulação de crescimento da planta |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
EP1805155B1 (en) * | 2004-10-25 | 2010-11-03 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
CN115304536B (zh) * | 2022-07-26 | 2023-09-22 | 合肥工业大学 | 一种吲哚啉-2-酮化合物衍生物的制备及用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2314242A1 (de) * | 1973-03-22 | 1974-09-26 | Bayer Ag | Neue 3-substituierte 2-oxo-4-hydroxy1,2,3,4-tetrahydrochinazolin-4-carbonsaeurehydrazide |
US4780477A (en) * | 1985-06-08 | 1988-10-25 | Kissei Pharmaceutical Co., Ltd. | Isatin compositions having anti-ulcer activities |
US4988710A (en) * | 1989-08-25 | 1991-01-29 | Washington University | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins |
IE69677B1 (en) * | 1989-12-11 | 1996-10-02 | Neurosearch As | Isatine derivatives their preparation and use |
-
1991
- 1991-03-15 US US07/670,061 patent/US5164404A/en not_active Expired - Fee Related
-
1992
- 1992-02-24 EP EP92103104A patent/EP0503349B1/en not_active Expired - Lifetime
- 1992-02-24 AT AT92103104T patent/ATE116639T1/de not_active IP Right Cessation
- 1992-02-24 ZA ZA921328A patent/ZA921328B/xx unknown
- 1992-02-24 ES ES92103104T patent/ES2069330T3/es not_active Expired - Lifetime
- 1992-02-24 DK DK92103104.3T patent/DK0503349T3/da active
- 1992-02-24 DE DE69201068T patent/DE69201068T2/de not_active Expired - Fee Related
- 1992-02-26 NZ NZ241752A patent/NZ241752A/en unknown
- 1992-02-26 AU AU11225/92A patent/AU643877B2/en not_active Ceased
- 1992-02-28 IE IE920643A patent/IE66111B1/en not_active IP Right Cessation
- 1992-03-11 FI FI921049A patent/FI103276B1/fi not_active IP Right Cessation
- 1992-03-12 CA CA002062853A patent/CA2062853A1/en not_active Abandoned
- 1992-03-13 NO NO921000A patent/NO180191C/no not_active IP Right Cessation
- 1992-03-13 KR KR1019920004115A patent/KR100192641B1/ko not_active IP Right Cessation
- 1992-03-13 JP JP05553192A patent/JP3407896B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-03 GR GR950400815T patent/GR3015671T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
IE66111B1 (en) | 1995-12-13 |
NO921000L (no) | 1992-09-16 |
KR100192641B1 (ko) | 1999-06-15 |
EP0503349B1 (en) | 1995-01-04 |
EP0503349A1 (en) | 1992-09-16 |
NZ241752A (en) | 1994-05-26 |
DE69201068T2 (de) | 1995-05-11 |
KR920017650A (ko) | 1992-10-21 |
JPH0578350A (ja) | 1993-03-30 |
NO180191B (no) | 1996-11-25 |
ES2069330T3 (es) | 1995-05-01 |
AU643877B2 (en) | 1993-11-25 |
US5164404A (en) | 1992-11-17 |
DE69201068D1 (de) | 1995-02-16 |
ZA921328B (en) | 1992-11-25 |
IE920643A1 (en) | 1992-09-23 |
FI103276B (fi) | 1999-05-31 |
JP3407896B2 (ja) | 2003-05-19 |
FI921049A0 (fi) | 1992-03-11 |
FI921049A (fi) | 1992-09-16 |
DK0503349T3 (da) | 1995-05-08 |
NO921000D0 (no) | 1992-03-13 |
ATE116639T1 (de) | 1995-01-15 |
GR3015671T3 (en) | 1995-07-31 |
AU1122592A (en) | 1992-09-17 |
FI103276B1 (fi) | 1999-05-31 |
CA2062853A1 (en) | 1992-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO180191C (no) | Hydrazonderivater, farmasöytiske preparater derav samt anvendelse av hydrazonforbindelser for fremstilling av et medikament | |
DK46789D0 (da) | 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf | |
HUP9701193A2 (hu) | N-(4-Aril-tiazol-2-il)-szulfonamid-származékok alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására, új származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0002830A2 (hu) | Indol- és 2,3-dihidroindol-származékok, előállításuk és gyógyászati alkalmazásuk | |
FI942310A (fi) | 1,3-substituoidut sykloalkeenit ja sykloalkaanit keskushermostoon vaikuttavina aineina | |
DK0432648T3 (da) | Isatinderivater, deres fremstilling og anvendelse | |
DE3852935D1 (de) | Substituierte Alpha-Aminosäuren mit pharmazeutischer Aktivität. | |
NO861868L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatian-derivater. | |
PT889044E (pt) | Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central | |
ZA892258B (en) | Use of isoxazolinones as cerebro-active drugs | |
SE8107833L (sv) | Substituerade tetrahydro-1,2,4-oxadiazin-5-on-derivat med kramplosande verkan, sett for deras framstellning och farmaceutiska beredningar innehallandedem | |
IT8509443A0 (it) | Interforometro per spettroscopia dell'ultravioletto e visibile del tipo trasformata di fourier, senza parti mobili | |
TH30603A (th) | สารประกอบแบบใหม่ | |
NO951100L (no) | 2-amino-4-fenyl-4-oksosmörsyrederivater med kynurinase- og/eller kynurenin-3-hydroksylase-inhiberende aktivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |